



Receipt of radiotherapy after mastectomy in women with breast cancer: Population-based cohort study in New Zealand

Phyu Mon Latt¹  | Sandar Tin Tin¹ | Mark Elwood¹ | Ross Lawrenson²  | Ian Campbell³

¹Section of Epidemiology and Biostatistics, School of Population Health, University of Auckland Tamaki Innovation Campus, Auckland, New Zealand

²National Institute of Demographic and Economic Analysis, University of Waikato, Hamilton, New Zealand

³Waikato Clinical Campus, University of Auckland, Hamilton, New Zealand

Correspondence

Phyu Mon Latt, Section of Epidemiology and Biostatistics, School of Population Health, University of Auckland Tamaki Innovation Campus, Auckland 1072, New Zealand.
Email: plat182@aucklanduni.ac.nz

Abstract

Purpose: To investigate the receipt of postmastectomy radiotherapy (PMRT) in breast cancer patients in New Zealand for whom radiotherapy is strongly recommended in current clinical guidelines.

Method: This study involved all women who were diagnosed with primary invasive breast cancer in two health regions, had undergone a mastectomy, and met the “strong recommendation” criteria for PMRT based on New Zealand National Guidelines. We performed logistic regression analyses to identify demographic and clinical factors associated with the receipt of PMRT.

Results: Of the 1455 patients with stage II to III cancers included in this analysis, 1195 (82%) received radiotherapy. The receipt of PMRT decreased with increasing age, and was significantly lower in rural residents, Māori and Pacific women, those with more comorbidity, those who received primary cancer care in a public facility, and those diagnosed with stage III cancer. Although not significant, the receipt was also lower in patients who resided in more deprived neighborhood, and those with comorbidities. The findings restricted to stage III patients ($n = 1325$), and to those diagnosed since 2010 ($n = 422$), after the current guidelines were published, which were very similar to the whole cohort.

Conclusion: Disparities exist in the receipt of PMRT in breast cancer patients in New Zealand, underscoring the need for a greater equity focus in management of breast cancer.

KEYWORDS

breast cancer, mastectomy, radiotherapy, utilization

1 | INTRODUCTION

Postmastectomy radiotherapy (PMRT) reduces the risk of locoregional recurrence and improves survival in appropriately selected women with breast cancer.^{1–3} In a large meta-analysis of randomized trials, PMRT in node positive women reduced 10-year locoregional recurrence as a first event from 26% to 8.1% and resulted in a relative risk of breast cancer death of 0.84% patients.⁴ In New Zealand, radiation treatment after a mastectomy is strongly recommended for patients whose tumor size is more than 5 cm, or have four or more positive axillary lymph nodes, or have a close surgical margin after mastectomy, as recommended in the National Guidelines published in 2009.⁵ Indications for PMRT have steadily broadened to lower the risk of recurrence over the last two decades. However, even in the high-risk groups, not all patients receive the recommended treatment.⁶

The receipt of radiotherapy after a mastectomy can be influenced by a number of factors, including patient demographics, tumor characteristics, and environmental factors.^{7–16} Demographic factors, such as race, age at diagnosis, urban/rural difference, and socioeconomic conditions, and tumor characteristics, such as stage, and so on, have been described as factors influencing the receipt of radiation therapy after a mastectomy.^{7–16} Distance to the radiation facility has been shown to reduce the receipt of the treatment in a variety of settings,^{8–13,16} but the results are not consistent. These findings from other countries may or may not be applicable to the New Zealand context.

We, therefore, investigated the receipt of PMRT in breast cancer patients in New Zealand for whom radiotherapy would be strongly recommended, to identify factors that have affected or been associated with the receipt of this treatment. This group was chosen as the New Zealand guidelines are similar to those in other countries, and the indications for use of PMRT in lower risk women are less clear.

2 | METHODS

2.1 | Study database

This population-based cohort study utilized the data from the Auckland Breast Cancer Register (ABCR) and the Waikato Breast Cancer Register (WBCR). The ABCR and WBCR are comprehensive regional population-based databases, and use the same core data. The ABCR has captured almost all newly diagnosed breast cancer cases in the Auckland, Counties Manukau, Waitemata District Health Board (DHB) regions since 2000 and the WBCR has recorded almost all patients in the Waikato DHB region from 1991 onward. The completeness of the WBCR has been checked against the legally mandated National Cancer Registry and was found to be 99% complete.¹⁷ The ABCR is also complete with 1% loss to follow-up.¹⁸ The registers recorded patients' National Health Index (NHI) number (a unique patient identifier), demographic details, disease factors, and treatment factors. Both databases contain more comprehensive and accurate information than national data sources.¹⁷⁻¹⁹

The registers are regularly linked to the National Cancer Registry, which contains information about all malignant tumors first diagnosed in New Zealand (except basal cell and squamous cell tumors of the skin), and the Mortality Collection, which contains information about all deaths registered in the country, using the NHI number. We also linked the data to the National Minimum Dataset, which contains information about patients discharged from all public and over 90% of private hospitals in New Zealand, to collect information on comorbidities.

2.2 | Study sample

We identified all patients who were diagnosed with breast cancer and had undergone a mastectomy with the date of diagnosis from 1 January 2000 to 30 June 2014 in the ABCR, and from 1 January 1991 to 30 June 2014 in the WBCR ($N = 16\ 111$). We excluded patients who received a mastectomy not as part of their primary treatment or who received a mastectomy due to local recurrence, those without axillary surgery, those who received chemotherapy prior to mastectomy for down staging of the disease, those with noninvasive breast cancer, those with metastatic breast cancer, those with a second new cancer, and male patients. Of the 6654 women identified, 1455 patients (22%) met the "strong recommendation" criteria for PMRT set by the New Zealand Guidelines⁵ based on tumor size (more than 5 cm) and number of lymph nodes (four or more). Eligibility based on the margin size was not considered as this information was not available.

2.3 | Variables of interest

The main study outcome was the receipt of PMRT. The potential predictors of interest include: patient demographics such as age, ethnicity and area of residence, disease characteristics such as tumor stage at diagnosis, grade, histology, hormone receptor status, comorbidity, and healthcare facility type where primary cancer treatment was undertaken. For staging, Tumor-Node-Metastasis (TNM) classification by American Joint Committee on Cancer Staging (7th Edition) was

used. The health domicile codes, which represent patients' residential addresses, were categorized as urban (main urban area, satellite urban community, and rural area with high urban influence), and rural areas (others) based on statistics New Zealand's urban/rural profile.²⁰ Main urban areas are centered on a city or main urban center and have a minimum population of 30 000; satellite urban communities are areas where 20% or more of the resident employed population work in a main urban area; and rural areas with high urban influence are areas where a significant proportion of the resident employed population work in a main urban area. The domicile codes were also mapped on to the 2006 New Zealand Deprivation Index (NZDep), and the degree of neighborhood deprivation was assessed using a one to ten decile scale with decile ten as the most deprived and decile one as the least.²¹ A C3 index score was used to measure patients' comorbidity. It is a cancer-specific index of comorbidity based on the presence of 42 chronic conditions recorded in the National Minimum Dataset for a period of 5 years prior to the diagnosis of cancer.²² Each condition was weighted by its impact on 1-year noncancer mortality in a cancer cohort, and the weights were then summed to get a final comorbidity score. This information was available for patients registered from 2000 onward only.

2.4 | Data analysis

We restricted our main analysis to the 1455 patients who were diagnosed with stages II to III breast cancer between 1991 and 2014 and for whom PMRT was "strongly recommended" in the guidelines. We compared demographic and clinical profiles between patients who received PMRT and those who did not by using chi-square tests. We then performed univariate and multivariate logistic regression analyses to identify factors associated with the receipt of PMRT. We undertook similar analyses by restricting analyses to patients diagnosed with stage III breast cancer only ($n = 1325$). We performed a sensitivity analysis by restricting analyses to the 422 patients who were registered from 2010 onward (after the most recent guidelines were published).

3 | RESULTS

Of the 1455 breast cancer patients who were diagnosed between 1991 and 2014 and met the "strong recommendation" criteria for PMRT, 1195 (82%) received radiotherapy and 260 (18%) did not (Table 1). The receipt of PMRT decreased substantially with age from the youngest to the oldest category. The odds ratio (OR), after control for demographic, clinical and pathological factors, for those aged 80+ was 0.19, with 95% confidence interval (CI) as 0.12-0.32, compared to middle-aged patients (50-59). Māori women were less likely to receive PMRT than New Zealand European women (adjusted OR, 0.60; 95% CI, 0.40-0.91), as were Pacific women (adjusted OR, 0.58; 95% CI, 0.36-0.95). Receipt of PMRT tended to decrease in groups with increasing social deprivation although the trend was not regular or significant (overall P value 0.09), rural residence was associated with a lower receipt of PMRT (adjusted OR, 0.65; 95% CI, 0.41-1.00). Breast cancer patients who received primary cancer care (mainly surgical treatment) at the private facility were more likely to receive PMRT than those at

TABLE 1 Sample characteristics, univariate and multivariate analyses by the receipt of PMRT among stages II and III breast cancer patients

Characteristics	Total sample	Received RT	Did not receive RT	Univariate analysis Crude OR (95% CI)	Multivariate analysis ¹ Adjusted OR (95% CI)	P value (Multivariate analyses)
Total	1455	1195 (82%)	260 (18%)			
Age Groups						
<40	176	155 (88%)	21 (12%)	1.38 (0.80-2.36)	1.56 (0.89-2.73)	<0.0001
40-49	408	354 (87%)	54 (13%)	1.22 (0.81-1.83)	1.20 (0.79-1.83)	
50-59	350	295 (84%)	55 (16%)	1	1	
60-69	247	205 (83%)	42 (17%)	0.91 (0.59-1.41)	0.92 (0.59-1.45)	
70-79	164	129 (79%)	35 (21%)	0.69 (0.43-1.10)	0.67 (0.41-1.09)	
80+	110	57 (52%)	53 (48%)	0.20 (0.13-0.32)	0.19 (0.12-0.32)	
Ethnicity						
European	999	831 (83%)	168 (17%)	1	1	0.02
Māori	181	136 (75%)	45 (25%)	0.61 (0.42-0.89)	0.60 (0.40-0.91)	
Pacific	132	101 (77%)	31 (23%)	0.66 (0.43-1.02)	0.58 (0.36-0.95)	
Others	143	127 (89%)	16 (11%)	1.61 (0.93-2.77)	1.15 (0.64-2.04)	
NZ Deprivation Codes						
NZDep 1 to 2 (least deprived)	278	250 (90%)	28 (10%)	1	1	0.09
NZDep 3 to 6	517	420 (81%)	97 (19%)	0.49 (0.31-0.76)	0.59 (0.37-0.96)	
NZDep 7 to 10 (most deprived)	660	525 (80%)	135 (20%)	0.44 (0.28-0.67)	0.63 (0.39-1.02)	
Urban/rural						
Urban	1271	1061 (83%)	210 (17%)	1	1	0.05
Rural	184	134 (73%)	50 (27%)	0.53 (0.37-0.76)	0.65 (0.41-1.00)	
Public/private						
Public	987	774 (78%)	213 (22%)	1	1	0.003
Private	468	421 (90%)	47 (10%)	2.47 (1.76-3.45)	1.73 (1.20-2.49)	
Register						
Auckland	1109	927 (84%)	182 (16%)	1	1	0.7
Waikato	346	268 (77%)	78 (23%)	0.67 (0.50-0.91)	0.93 (0.63-1.38)	
Stage						
II	130	101 (78%)	29 (22%)	0.74 (0.48-1.14)	0.74 (0.46-1.19)	0.2
III	1325	1094 (83%)	231 (17%)	1	1	
Grade						
1 (Well-differentiated)	109	83 (76%)	26 (24%)	1	1	0.2
2 (Moderately differentiated)	704	590 (84%)	114 (16%)	1.62 (1.00-2.63)	1.60 (0.95-2.70)	
3 (Poorly differentiated)	642	522 (81%)	120 (19%)	1.36 (0.84-2.21)	1.55 (0.89-2.70)	
Histology						
Ductal	1081	880 (81%)	201 (19%)	1	1	0.8
Lobular	292	251 (86%)	41 (14%)	1.40 (0.97-2.01)	1.16 (0.76-1.79)	
Others	82	64 (78%)	18 (22%)	0.81 (0.47-1.4)	1.08 (0.59-2.00)	
ER/PR Status						
ER/PR both positive	867	736 (85%)	131 (15%)	1	1	0.03
ER or PR positive	244	189 (77%)	55 (23%)	1.62 (1.00-2.63)	0.65 (0.44-0.95)	
ER/PR both negative	344	270 (78%)	74 (22%)	1.36 (0.84-2.21)	0.67 (0.46-0.98)	
C3 index						
0 (No comorbid conditions)	1102	940 (85%)	162 (15%)	1		
1	101	86 (85%)	15 (15%)	0.99 (0.56-1.75)		
2	68	45 (66%)	23 (34%)	0.34 (0.20-0.57)		

(Continues)

TABLE 1 (Continued)

Characteristics	Total sample	Received RT	Did not receive RT	Univariate analysis Crude OR (95% CI)	Multivariate analysis ¹ Adjusted OR (95% CI)	P value (Multivariate analyses)
3 (Maximum)	101	61 (60%)	40 (40%)	0.26 (0.17-0.41)		
Missing/Unknown	83	63 (76%)	20 (24%)			

¹Multivariate analysis: adjusted for all variables in the table including year of diagnosis.

ER, estrogen receptor; PR, progesterone receptor; RT, radiotherapy; 95% CI, 95% confidence interval.

Regarding C3 index, linkage to the hospital discharge data was done only for patients who were registered 2000 onward, which resulted in high number of missing values in C3 index; it was not included in the multivariate analysis.

the public health facilities (adjusted OR, 1.73; 95% CI, 1.20-2.49). After control of other factors, the use in the two regions was similar.

Regarding clinical factors, the receipt of PMRT was significantly lower in patients with hormone receptor negative tumors, and tended to be lower in those with stage II and with well-differentiated tumors (Table 1). The receipt of PMRT was much lower in those with more comorbidity, assessed by higher C3 index scores.

A further analysis was restricted to patients with stage III breast cancer, as the recommendations for PMRT are more generally accepted in this group. Demographic factors had similar or stronger associations in stage III patients, with significantly less PMRT use in patients who were older, Māori or Pacific ethnicity, and had public rather than private health care (Table 2). The associations with clinical and pathological factors were comparable to those in the larger cohort, but weaker, as expected as the range is narrower; however, PMRT usage was lower in patients with receptor negative tumors.

As the current guidelines for breast cancer treatment were published in 2009, further analyses were based on patients diagnosed from 2010 onward as a sensitivity test to see if the overall results applied to this subgroup. The findings were similar, not suggesting any substantial changes, although, with the smaller sample size, some associations were no longer significant (Table 3). The proportion of patients getting PMRT was 81% (832/1033) from 1991 to 2009, and 86% (363/422) in 2010 to 2014 ($P = 0.01$).

4 | DISCUSSION

We found that only 82% of patients who met the “strong recommendation” criteria for PMRT (based on tumor size and number of lymph nodes involved) received the treatment. The receipt of PMRT was influenced by a number of demographic factors such as age, ethnicity, area of residence (urban/rural), and healthcare facility type (public/private). Māori and Pacific patients were significantly less likely to receive PMRT, even after control of other factors including social deprivation. In addition, clinical factors, such as hormone receptor status and comorbidity, affected the use of PMRT.

This study is based on the data from two prospectively maintained population-based registers that contained comprehensive information about patients diagnosed with primary breast cancer. Linkage to the national databases enabled the study to ascertain information on cause of death and on associated comorbidities. There may be mis-

classification in identifying patients who were strongly indicated for PMRT as information on the size of tumor margin, a criterion used in the guidelines for recommendation of PMRT, was not available. Particularly, this analysis may have excluded some patients with stage I, who met the “strong recommendation” criteria due to involved margins. We were not able to assess the effect of some potentially important factors, such as smoking, alcohol or body mass index, as such information was not available. Some findings may be affected by data inaccuracy, for example, information on ethnicity recorded in the Auckland Registry is based on that linked to the NHI, which may result in undercounting of Māori population and underestimation of associations. The New Zealand deprivation score, NZDep 2006, used in the analyses measures area-level deprivation and may not fully reflect an individual's actual socioeconomic status although it has been validated previously.²³

Clinical guidelines are not standards of practice, and are designed to clarify the appropriate treatment for patients who show certain characteristics. Clinicians are expected to be aware of the guidelines, but not to apply them automatically, and need to take into account the individual situation of each patient. There are a number of possible contraindications to PMRT, including connective tissue diseases like systemic lupus erythematosus, or severe respiratory disease, or inability to lie flat or still or with the arm abducted. Further, the actual utilization of radiotherapy depends on a shared decision between the doctor and the patient, and patient choice may influence utilization. However, there was limited information in the dataset about whether the receipt or nonreceipt of PMRT was due to the doctor's choice or patients' choice.

The general impression from the clinical factors considered is that even though radiotherapy is strongly recommended in the guidelines for all the patients in this analysis, clinical factors that confer a higher risk of recurrence or death from breast cancer result in a greater utilization of radiotherapy; such as stage III disease and poor differentiation. This suggests that in patients without these high-risk factors either clinicians advocate with less enthusiasm, or do not advocate radiotherapy despite it being recommended in the guidelines, or the patient decides that they do not want radiotherapy. Both situations may be rationalized on the basis that in lower risk patients, it is likely that the potential benefits of radiotherapy are lower while the disadvantages of the treatment remain similar, so that the likely risk-benefit equation is less favorable to treatment. However, it could be asked whether such considerations could be taken into account to a greater extent in future guidelines, so that there would

TABLE 2 Sample characteristics, univariate and multivariate analyses by the receipt of PMRT among stage III breast cancer patients

Characteristics	Total sample	Received RT	Did not receive RT	Univariate analysis Crude OR (95% CI)	Multivariate analysis ¹ Adjusted OR (95% CI)	P value (Multivariate analyses)
Total	1325	1094 (83%)	231 (17%)			
Age Groups						
<40	168	147 (88%)	21 (13%)	1.25 (0.72-2.17)	1.46 (0.83-2.59)	<0.0001
40-49	367	319 (87%)	48 (13%)	1.19 (0.77-1.83)	1.16 (0.74-1.81)	
50-59	323	274 (85%)	49 (15%)	1	1	
60-69	226	190 (84%)	36 (16%)	0.94 (0.59-1.51)	0.97 (0.60-1.58)	
70-79	143	114 (80%)	29 (20%)	0.70 (0.42-1.17)	0.65 (0.38-1.10)	
80+	98	50 (51%)	48 (49%)	0.19 (0.11-0.31)	0.17 (0.10-0.29)	
Ethnicity						
European	912	766 (84%)	146 (16%)	1	1	0.02
Māori	166	125 (75%)	41 (25%)	0.58 (0.39-0.86)	0.56 (0.36-0.86)	
Pacific	122	94 (77%)	28 (23%)	0.64 (0.41-1.01)	0.55 (0.33-0.91)	
Others	125	109 (87%)	16 (13%)	1.30 (0.75-2.26)	0.88 (0.49-1.58)	
NZ Deprivation Codes						
NZDep 1 to 2 (least deprived)	254	231 (91%)	23 (9%)	1	1	0.05
NZDep 3 to 6	472	382 (81%)	90 (19%)	0.42 (0.26-0.69)	0.52 (0.31-0.88)	
NZDep 7 to 10 (most deprived)	599	481 (80%)	118 (20%)	0.41 (0.25-0.65)	0.58 (0.34-0.99)	
Urban/rural						
Urban	1155	968 (84%)	187 (16%)	1	1	0.2
Rural	170	126 (74%)	44 (26%)	0.55 (0.38-0.81)	0.71 (0.44-1.14)	
Public/private						
Public	900	710 (79%)	190 (21%)	1	1	0.005
Private	425	384 (90%)	41 (10%)	2.51 (1.75-3.59)	1.74 (1.18-2.57)	
Register						
Auckland	1014	853 (84%)	161 (16%)	1	1	0.3
Waikato	311	241 (77%)	70 (23%)	0.65 (0.47-0.89)	0.79 (0.52-1.21)	
Grade						
1 (Well-differentiated)	91	71 (78%)	20 (22%)	1	1	0.5
2 (Moderately differentiated)	642	539 (84%)	103 (16%)	1.47 (0.86-2.53)	1.44 (0.80-2.59)	
3 (Poorly differentiated)	592	484 (82%)	108 (18%)	1.26 (0.74-2.16)	1.43 (0.77-2.64)	
Missing/Unknown						
Histology						
Ductal	1020	830 (81%)	190 (19%)	1	1	0.4
Lobular	243	211 (87%)	32 (13%)	1.51 (1.01-2.26)	1.20 (0.75-1.90)	
Others	62	53 (85%)	9 (15%)	1.35 (0.65-2.78)	1.66 (0.75-3.67)	
ER/PR Status						
ER/PR both positive	788	672 (85%)	116 (15%)	1	1	0.06
ER or PR positive	220	172 (78%)	48 (22%)	0.62 (0.43-0.90)	0.67 (0.45-1.01)	
ER/PR both negative	317	250 (79%)	67 (21%)	0.64 (0.46-0.90)	0.68 (0.46-1.00)	
C3 index						
0 (No comorbid conditions)	999	860 (86%)	139 (14%)	1		
1	93	80 (86%)	13 (14%)	1.00 (0.54-1.84)		
2	62	40 (65%)	22 (35%)	0.29 (0.17-0.51)		

(Continues)

TABLE 2 (Continued)

Characteristics	Total sample	Received RT	Did not receive RT	Univariate analysis Crude OR (95% CI)	Multivariate analysis ¹ Adjusted OR (95% CI)	P value (Multivariate analyses)
3 (Maximum)	93	56 (60%)	37 (40%)	0.25 (0.16-0.39)		
Missing/Unknown	78	58 (74%)	20 (26%)			

¹Multivariate analysis- adjusted for all variables in the table including year of diagnosis.

ER indicates estrogen receptor; PR, progesterone receptor; RT, radiotherapy; 95% CI, 95% confidence interval.

Regarding C3 index, linkage to the hospital discharge data was done only for patients registered 2000 onward which resulted in high number of missing values in C3 index; it was not included in the multivariate analysis.

be less variation between the guideline recommendation and actual clinical practice. For example, is it appropriate for the guidelines to recommend radiotherapy for patients over the age of 80 years, as it is known that the risk of locoregional recurrence tends to decrease with increasing age,²⁴ and older women often have comorbidities that may be a relative contraindication to PMRT (eg, chronic obstructive airway disease, or severe ischemic heart disease). Competing risks for life expectancy also increase with age, so that benefits of treatment are less for older women. This analysis shows that in reality, radiotherapy is much less used in these patients.

The evidence for the benefits of PMRT has increased over the period of this study, with major trials reported in 1997 and 1999¹⁻³ and a major overview in 2005.¹ The New Zealand guidelines were published in 2009, although many breast cancer clinicians were involved or aware of earlier drafts and discussions. Despite this strengthening of published evidence, features associated with receipt of PMRT did not change greatly over this period.

Overall, this analysis on a population-based series of breast cancer patients shows that 18% of patients for whom radiotherapy is recommended in current clinical guidelines, do not receive this treatment. This situation may compare well to other estimates, for example, on New South Wales, Australia data, it was estimated that optimally 82% of breast cancer patients should get radiotherapy, but only 54% received it.^{25,26} Some of these variations may be explicable on the basis that radiotherapy is used by patients with clinical indications conferring a higher risk of poor outcome and greater potential benefits from radiotherapy. This does suggest that clinicians in practice are more cautious in their recommendations for radiotherapy than the guideline criteria would indicate. This may be an acceptable situation, but further work on the criteria for recommendation of radiotherapy, and the criteria for acceptance of radiotherapy by the patient, would be needed to understand this process further. Some information on referrals and patient choice was recorded, but this information may be questionable. It shows that of the 260 patients not receiving radiotherapy, 131 (50%) did not get a referral to a radiation oncologist (but whether no referral was offered, or the patient declined to be referred is unknown). A further 11 (4%) patients had a referral but did not attend, and 65 (25%) patients declined the offer of radiotherapy. Thus, 46 patients (18%) were offered radiotherapy, apparently accepted it initially, but did not receive the treatment. However, we feel that this information should not be accepted without further validation.

The variations in radiotherapy utilization in terms of demographic factors, shown as substantial and significant variations in analy-

ses which have taken into account the relevant clinical factors, are less understandable and seem less acceptable. The diminished radiotherapy uptake with increasing age has been shown in several studies,^{7,9,12,14,15} and may be explicable on the basis that the potential benefits to individual patients are smaller, and the potential risks and threats to quality of life greater in older patients. This may apply to patients at more advanced ages, but does not readily explain why the utilization of radiotherapy, for example, in stage III patients aged 50-59 years is lower than the utilization in patients under 40 years of age.

Similarly, it is difficult to understand why utilization is lower in Māori and Pacific women than in European women, given that key clinical factors, such as staging, has been taken into account. The tendency for reduced utilization in more deprived social groups, and the lower utilization in rural resident patients, along with this ethnic variation, suggests that utilization depends on economics, access, and other social factors, in addition to recognized clinical indications. This, in turn, suggests that further effort should be made to understand these factors and take actions to reduce the impact, which would include attention to the economic circumstances, opportunities for travel, and competing demands in jobs and family care responsibilities, which affect cancer patients, particularly those with more disadvantaged social circumstances. The lower uptake of radiotherapy by rural women has potential implications for use of radiotherapy in other breast cancer situations. Current techniques require women to attend a major center 5 days a week for 3 to 5 weeks for treatment. This poses challenges for women who live at some distance from these centers, and are potentially forced to travel, or live away from family, friends, and other home support during treatment.

Whether patient choice factors are important in relating to the low utilization of radiotherapy by Māori and Pacific women is clearly an important question, which has hardly been explored. The contrast to these findings is the higher utilization in patients treated in private facilities; whether this relates to any difference in the way radiotherapy is advocated to such patients, or relates to patient choice, or is a reflection of the likely easier economic circumstances of such patients in being able to accept radiotherapy, would be worthy of further exploration.

To conclude, in this population-based series of stages II to III breast cancer patients for whom PMRT is recommended in the current clinical guidelines, only 82% actually received this treatment. Patients with features of more advanced or aggressive disease tended to receive radiotherapy more often, which may be appropriate. But after adjusting for clinical and pathological features, demographic factors, such as

TABLE 3 Comparison of adjusted odds ratios for breast cancer patients registered from 2000, with the whole cohort

Factors	From 1991 Stage II and III patients registered from 1991 (n = 1455)		From 2010 Stage II and III patients registered from 2010 (n = 422)		From 1991 Stage III patients registered from 1991 (n = 1325)		From 2010 Stage III patients registered from 2010 (n = 377)	
	Number	Adjusted OR (95% CI)	Number	Adjusted OR (95% CI)	Number	Adjusted OR (95% CI)	Number	Adjusted OR (95% CI)
Age Groups								
<40	176	1.56 (0.89-2.73)	39	2.72 (0.67-10.99)	168	1.46 (0.83-2.59)	38	2.79 (0.66-11.82)
40-49	408	1.20 (0.79-1.83)	129	1.82 (0.75-4.41)	367	1.16 (0.74-1.81)	113	1.83 (0.69-4.83)
50-59	350	1	94	1	323	1	85	1
60-69	247	0.92 (0.59-1.45)	82	1.46 (0.54-3.96)	226	0.97 (0.60-1.58)	72	1.61 (0.53-4.93)
70-79	164	0.67 (0.41-1.09)	41	0.96 (0.29-3.20)	143	0.65 (0.38-1.10)	35	0.70 (0.20-2.41)
80+	110	0.19 (0.12-0.32)	37	0.16 (0.06-0.45)	98	0.17 (0.10-0.29)	34	0.12 (0.04-0.38)
Ethnicity								
European	999	1	281	1	912	1	253	1
Māori	181	0.60 (0.40-0.91)	46	0.56 (0.21-1.54)	166	0.56 (0.36-0.86)	40	0.40 (0.13-1.18)
Pacific	132	0.58 (0.36-0.95)	49	0.59 (0.21-1.67)	122	0.55 (0.33-0.91)	44	0.47 (0.15-1.47)
Others	143	1.15 (0.64-2.04)	46	0.53 (0.19-1.49)	125	0.88 (0.49-1.58)	40	0.37 (0.13-1.10)
NZ Deprivation Codes								
NZDep 1 to 2 (least deprived)	278	1	100	1	254	1	90	1
NZDep 3 to 6	517	0.59 (0.37-0.96)	153	1.08 (0.42-2.73)	472	0.52 (0.31-0.88)	136	1.00 (0.37-2.73)
NZDep 7 to 10 (most deprived)	660	0.63 (0.39-1.02)	169	0.69 (0.26-1.85)	599	0.58 (0.34-0.99)	151	0.79 (0.27-2.35)
Urban/rural								
Urban	1271	1	43	1	1155	1	340	1
Rural	184	0.65 (0.41-1.00)	379	0.29 (0.10-0.82)	170	0.71 (0.44-1.14)	37	0.30 (0.10-0.94)
Public/private								
Public	987	1	275	1	900	1	245	1
Private	468	1.73 (1.20-2.49)	147	1.36 (0.61-3.07)	425	1.74 (1.18-2.57)	132	1.52 (0.63-3.71)
Register								
Auckland	1109	1	351	1	1014	1	316	1
Waikato	346	0.93 (0.63-1.38)	71	2.11 (0.70-6.33)	311	0.79 (0.52-1.21)	61	1.69 (0.53-5.43)
Stage								
II	130	0.74 (0.46-1.19)	45	1.28 (0.46-3.57)				
III	1325	1	377	1				
Grade								
1 (Well-differentiated)	109	1	32	1	91	1	23	1
2 (Moderately differentiated)	704	1.60 (0.95-2.70)	210	1.70 (0.53-5.45)	642	1.44 (0.80-2.59)	188	1.76 (0.43-7.22)
3 (Poorly differentiated)	642	1.55 (0.89-2.70)	180	1.54 (0.45-5.30)	592	1.43 (0.77-2.64)	166	1.65 (0.38-7.20)
Histology								
Ductal	1081	1	301	1	1020	1	284	1
Lobular	292	1.16 (0.76-1.79)	97	0.51 (0.22-1.19)	243	1.20 (0.75-1.90)	74	0.48 (0.19-1.18)
Others	82	1.08 (0.59-2.00)	24	1.26 (0.25-6.35)	62	1.66 (0.75-3.67)	19	1.56 (0.18-13.5)
ER/PR Status								
ER/PR both positive	867	1	282	1	788	1	249	1
ER or PR positive	244	0.65 (0.44-0.95)	53	0.67 (0.24-1.83)	220	0.67 (0.45-1.01)	46	0.44 (0.15-1.24)
ER/PR both negative	344	0.67 (0.46-0.98)	87	0.83 (0.35-1.94)	317	0.68 (0.46-1.00)	82	1.04 (0.42-2.61)
C3 index								
0 (No comorbid conditions)	1102		337	1	999		300	0.46 (0.16-1.31)
1	101		37	2.37 (0.64-8.82)	93		34	1

(Continues)

TABLE 3 (Continued)

Factors	From 1991		From 2010		From 1991		From 2010	
	Stage II and III patients registered from 1991 (n = 1455)		Stage II and III patients registered from 2010 (n = 422)		Stage III patients registered from 1991 (n = 1325)		Stage III patients registered from 2010 (n = 377)	
	Number	Adjusted OR (95% CI)	Number	Adjusted OR (95% CI)	Number	Adjusted OR (95% CI)	Number	Adjusted OR (95% CI)
2	68		21	1.02 (0.28-3.76)	62		20	
3 (Maximum)	101		27	0.68 (0.23-2.06)	93		23	0.29 (0.07-1.19)
Missing/Unknown	83				78			

Adjusted ORs: adjusted for other variables in the table including year of diagnosis.

ER estrogen receptor; PR, progesterone receptor; 95% CI, 95% Confidence interval.

Regarding C3 index, linkage to the hospital discharge data was done only for patients registered 2000 onward.

age, ethnicity, deprivation status, residing area (urban/rural), and public/private healthcare status, had significant effects on the receipt of radiotherapy. Utilization patterns did not show substantial changes in more recent years, after publication of the guidelines.

ACKNOWLEDGMENTS

This study was funded by the New Zealand Breast Cancer Foundation. Phyu Mon Latt was supported by the NZAID Scholarship for her Master's studies at the University of Auckland. We thank the Auckland Breast Cancer Study Group, Waikato Breast Cancer Trust, Waikato Bay of Plenty Division of the Cancer Society, and the Ministry of Health for maintaining and providing the required data, and Drs Erica Whineray-Kelly and Glenys Round for advice.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

ORCID

Phyu Mon Latt  <http://orcid.org/0000-0001-5880-5731>

Ross Lawrenson  <http://orcid.org/0000-0003-0437-8839>

REFERENCES

1. Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. *Lancet*. 2005;366:2087-2106.
2. Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. *N Engl J Med*. 1997;337:949-955.
3. Overgaard M, Jensen M, Overgaard J, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomized trial. *Lancet*. 1999;353:1641-1648.
4. EBCTCG (Early Breast Cancer Trialists' Collaborative Group), McGale P, Taylor C, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomized trials. *Lancet*. 2014;383:2127-2135.
5. Ministry of Health. *Management of Early Breast Cancer: evidence-based Best Practice Guideline*. Wellington, New Zealand: New Zealand Guidelines Group (NZGG); 2009. <http://www.health.govt.nz/publication/management-early-breast-cancer-evidence-based-best-practice-guideline>
6. Tin Tin S, Elwood JM, Lawrenson R, Campbell I, Harvey V, Seneviratne S. Differences in breast cancer survival between public and private care in New Zealand: which factors contribute? *PLoS One*. 2016;11:e0153206.
7. Dragun AE, Huang B, Tucker TC, Spanos WJ. Disparities in the application of adjuvant radiotherapy after breast-conserving surgery for early stage breast cancer: impact on overall survival. *Cancer*. 2011;117:2590-2598.
8. Meden T, St John-Larkin C, Hermes D, Sommerschild S. Relationship between travel distance and utilization of breast cancer treatment in rural northern Michigan. *JAMA*. 2002;287:111. <https://doi.org/10.1001/jama.287.1.111-JMS0102-5-1>
9. Wheeler SB, Kuo TM, Durham D, Frizzelle B, Reeder-Hayes K, Meyer AM. Effects of distance to care and rural or urban residence on receipt of radiation therapy among North Carolina Medicare enrollees with breast cancer. *N C Med J*. 2014;75:239-246.
10. Athas WF, Adams-Cameron M, Hunt WC, Amir-Fazli A, Key CR. Travel distance to radiation therapy and receipt of radiotherapy following breast-conserving surgery. *J Natl Cancer Inst*. 2000;92:269-271.
11. Tyldesley S, McGahan C. Utilization of radiotherapy in rural and urban areas in British Columbia compared with evidence-based estimates of radiotherapy needs for patients with breast, prostate and lung cancer. *Clin Oncol (R Coll Radiol)*. 2010;22:526-532.
12. Fong A, Shafiq J, Saunders C, et al. A comparison of surgical and radiotherapy breast cancer therapy utilization in Canada (British Columbia), Scotland (Dundee), and Australia (Western Australia) with models of "optimal" therapy. *Breast*. 2012;21:570-577.
13. Sharma DK. Does increased geographical distance to a radiation therapy facility act as a barrier to seeking treatment? *Aust Med Stud J*. 2015;7:14.
14. Hershman DL, Buono D, McBride RB, et al. Surgeon characteristics and receipt of adjuvant radiotherapy in women with breast cancer. *J Natl Cancer Inst*. 2008;100:199-206.
15. Yeboa DN, Xu X, Jones BA, Soulos P, Gross C, Yu JB. Trend in age and racial disparities in the receipt of post-lumpectomy radiation therapy for stage I breast cancer. *Am J Clin Oncol*. 2016;39(6):568-574.
16. Wheeler SB, Carpenter WR, Peppercorn J, Schenck AP, Weinberger M, Biddle AK. Structural/organizational characteristics of health services partly explain racial variation in timeliness of radiation therapy among elderly breast cancer patients. *Breast Cancer Res Treat*. 2012;133:333-345.

17. Seneviratne S, Campbell I, Scott N, Shirley R, Peni T, Lawrenson R. Accuracy and completeness of the New Zealand cancer registry for staging of invasive breast cancer. *Cancer Epidemiol.* 2014;38:638–644.
18. Neave L, Harvey V, Benjamin C, et al. The Auckland Breast Cancer Register: a special project of the Auckland Breast Cancer Study Group. *N Z Med J.* 2003;116:U648.
19. Gurney J, Sarfati D, Dennett E, Koea J. The completeness of cancer treatment data on the National Health Collections. *N Z Med J.* 2013;126:69–74.
20. Statistics New Zealand. *New Zealand: urban/rural profile.* Wellington, New Zealand: Statistics New Zealand; 2007. http://www.stats.govt.nz/browse_for_stats/Maps_and_geography/Geographic-areas/urban-rural-profile-update.aspx
21. Salmond C, Crampton P, Atkinson J. *NZDep2006: Index of Deprivation.* Wellington, New Zealand: Department of Public Health, University of Otago; 2007. <http://www.otago.ac.nz/wellington/departments/public-health/research/hirp/otago020194.html>
22. Sarfati D, Gurney J, Stanley J, et al. Cancer-specific administrative data-based comorbidity indices provided valid alternative to Charlson and National Cancer Institute Indices. *J Clin Epidemiol.* 2014;67:586–595.
23. Salmond CE, Crampton P. Development of New Zealand's deprivation index (NZDep) and its uptake as a national policy tool. *Can J Public Health.* 2012;103:S7–S11.
24. Kong I, Narod SA, Taylor C, et al. Age at diagnosis predicts local recurrence in women treated with breast-conserving surgery and postoperative radiation therapy for ductal carcinoma in situ: a population-based outcomes analysis. *Curr Oncol.* 2014;21:e96–e104.
25. Batumalai V, Shafiq J, Gabriel G, Hanna TP, Delaney GP, Barton M. Impact of radiotherapy underutilisation measured by survival short-fall, years of potential life lost and disability-adjusted life years lost in New South Wales. *Radiother Oncol.* 2018;10.
26. Delaney G, Barton M, Jacob S. Estimation of an optimal radiotherapy utilization rate for breast carcinoma: a review of the evidence. *Cancer.* 2003;98:1977–1986.

How to cite this article: Latt PM, Tin Tin S, Elwood M, Lawrenson R, Campbell I. Receipt of radiotherapy after mastectomy in women with breast cancer: Population-based cohort study in New Zealand. *Asia-Pac J Clin Oncol.* 2018;1–9. <https://doi.org/10.1111/ajco.13101>